the CEO of NewBridge Pharmaceuticals Interview with CNBC
Watch CNBC Arabia’s episode “Made in UAE” Documentary featuring Joe Henein, President and CEO of NewBridge Pharmaceuticals, and his colleagues talk about NewBridge’s Journey on its 10th year anniversary, highlighting the UAE’s support for entrepreneurship and diversity on the link below
CAPHOSOL® CAPHOSOL DISPERSIBLE®
Caphosol® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions to lubricate the mucosa of the mouth, tongue and oropharynx and help maintain the integrity of the oral cavity. Caphosol® is available as ampules or in dispersible form.
|Description||LATUDA® is a once-daily oral atypical antipsychotic. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet medical needs of schizophrenia patients treated with current antipsychotics.|
|Indication||LATUDA® is indicated for the treatment of schizophrenia in adults aged 18 years and over.|
18.5 mg, 37 mg and 74 mg film coated tablets
FDA approved in October 2010
EMA approved in March 2014
Latuda® tablets are registered in UAE and KSA.
Guardant360® assay is a liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw. Test results are available in approximately seven days upon receipt in the US laboratory.
The test is done using circulating tumor DNA (ctDNA), which is produced when tumors shed small pieces or their genetic material into the bloodstream.
Guardant360® assay examines a panel of 74 genes (specifications) to identify any alterations in the tumor DNA.
Since its launch in 2014, Guardant360® assay has been ordered by more than 6,000 oncologists over 100,000 times for patients with advanced cancer to help select treatment.
|Use and indication||
To know more about Guardant360® assay please visit the https://www.guardanthealthamea.com or click on this link
NewBridge Pharmaceuticals -2018 winner of the Most Innovative Pharmaceutics Commercialisation Partner MENA award
“The www.CFI.co judging panel applauds the company’s mission to address unmet medical needs in the MENA region through strategic joint-ventures and partnerships, naming NewBridge Pharmaceuticals the 2018 winner of the Most Innovative Pharmaceutics Commercialisation Partner MENA award.”
NewBridge Pharmaceuticals at WCO-IOF-ESCEO Paris 2019
Joe Henein, the President & CEO of NewBridge Pharmaceuticals, Sherif Hamdy Franchise Head Metabolic Care and Lina Sabbagh Commercial Lead CNS Lebanon attended the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) in Paris from April 4th till 7th, 2019 along with the Abiogen team.
NewBridge Pharmaceuticals at EASL 2019
NewBridge President and CEO Joe Henein, Business Director Group Franchise Hisham EL Sayed and Brand Manager Rare Diseases Jennifer Bteich, attended The International Liver Congress “EASL 2019”, that was held in Vienna-Austria from April 10-14th along with Intercept team.
This year, EASL witnessed one of the most exciting and biggest study about NASH (Non-Alcoholic Steatohepatitis) that was presented for the first time during the congress.
Multiple Products, Multiple Geographies
TBY talks to Joe Henein, CEO of NewBridge Pharmaceuticals, on building brands, supporting SMEs in the region, and driving innovation.
To read more, click on this link.
Source Article: thebusinessyear